How They Work
Three receptors. Three different sets of levers.
Each receptor type is a distinct signaling pathway. When a medication activates one, it triggers specific downstream effects in your brain, gut, pancreas, liver, and fat tissue. More receptors targeted means more metabolic levers pulled simultaneously.
Receptor 1 — All three medications
GLP-1 — “The Appetite Brake”
Glucagon-Like Peptide-1 receptor
Semaglutide
Tirzepatide
Retatrutide
Slows your stomach down
Food moves through your stomach more slowly, extending fullness after smaller meals.
Turns down hunger at the source
Acts directly on the hypothalamus — your brain's hunger control center — reducing appetite signals before they even become conscious cravings.
Triggers "I'm full" signals sooner
Activates the brainstem's satiety center, so the message to stop eating arrives earlier in a meal and lasts longer after it.
Stabilizes blood sugar
Prompts the pancreas to release insulin when blood sugar rises — and only then, making it safe without risking dangerous blood sugar drops in healthy individuals.
Quiets food cravings and reward-driven eating
Influences the brain's dopamine reward pathways, reducing the pull toward high-calorie foods. Many patients also notice a marked decrease in alcohol cravings — same mechanism.
Receptor 2 — Tirzepatide + Retatrutide
GIP — “The Amplifier”
Glucose-Dependent Insulinotropic Polypeptide receptor
Tirzepatide
Retatrutide
Amplifies what GLP-1 started
Works in synergy with GLP-1 to produce significantly stronger appetite suppression and blood sugar control than either signal alone. It's not additive — it multiplies the effect.
Directs fuel toward muscle
Helps route glucose and available energy toward metabolically active muscle tissue rather than fat storage — relevant to body composition, not just the number on the scale.
Additional brain-level satiety support
GIP receptors in the brain reinforce the appetite-suppressing signals from GLP-1, contributing to the stronger satiety response seen with dual-agonist medications.
Supports bone health
GIP receptors in bone tissue promote bone formation — a benefit independent of its metabolic effects, relevant for adults managing bone density.
Receptor 3 — Retatrutide only
Glucagon — “The Furnace”
Glucagon receptor (GCGR)
Retatrutide only
Raises your resting calorie burn
Increases thermogenesis — your body burns more calories simply existing. This is distinct from anything the other two medications do: it adds genuine metabolic expenditure, not just appetite reduction.
Unlocks stored fat to be burned as fuel
Signals fat cells to actively release stored fat (lipolysis) so the body can use it for energy — the key mechanism driving deeper fat loss compared to GLP-1 alone.
Targets liver fat directly
Directly promotes the breakdown of fat stored in the liver (hepatic steatosis) — a metabolic risk factor that many active adults carry silently, often undetected.
Shifts from intake-reduction to output-increase
While GLP-1 reduces what goes in, glucagon agonism increases what gets burned. Together they create a true double-sided metabolic effect — the reason early data shows markedly greater weight loss.
Side-by-Side Comparison
What each medication actually does
Colored checkmarks indicate active mechanisms. Gray circles indicate pathways that drug does not target.
| Mechanism |
Semaglutide
Ozempic / Wegovy
GLP-1
GIP
Glucagon
|
Tirzepatide
Mounjaro / Zepbound
GLP-1
GIP
Glucagon
|
Retatrutide
Triple agonist — investigational
GLP-1
GIP
Glucagon
|
|---|---|---|---|
| GLP-1 Receptor Mechanisms — present in all three medications | |||
|
Slows gastric emptying
Food lingers in the stomach longer; fullness is extended after smaller amounts
|
✓ | ✓ | ✓ |
|
Reduces hunger via brain signaling
Hypothalamus and brainstem receive direct satiety signals, suppressing appetite centrally
|
✓ | ✓ | ✓ |
|
Blood sugar control
Glucose-dependent insulin release from the pancreas; suppresses liver glucose output
|
✓ | ✓ | ✓ |
|
Reduces cravings & reward-driven eating
Modulates brain dopamine reward pathways; reduces urge toward high-calorie foods and alcohol
|
✓ | ✓ | ✓ |
| GIP Receptor Mechanisms — added in Tirzepatide and Retatrutide | |||
|
Amplifies insulin and satiety signaling
Synergistic boost to GLP-1 effects; significantly stronger than GLP-1 alone
|
✕ | ✓ | ✓ |
|
Routes glucose toward muscle tissue
Preferential fuel delivery to metabolically active muscle over fat storage
|
✕ | ✓ | ✓ |
| Glucagon Receptor Mechanisms — exclusive to Retatrutide | |||
|
Increases resting calorie burn
Thermogenic effect — more calories burned at rest, independent of diet or exercise changes
|
✕ | ✕ | ✓ |
|
Mobilizes stored body fat as fuel
Lipolysis — fat cells release stored fat to be actively burned, not just blocked from growing
|
✕ | ✕ | ✓ |
|
Directly targets liver fat
Promotes breakdown of hepatic fat — addresses a metabolic risk factor many carry unknowingly
|
✕ | ✕ | ✓ |
Clinical Trial Data
What the evidence shows for body weight reduction
More receptor targets has correlated with greater average weight loss across major trials. These figures represent average results; individual outcomes vary based on dose, adherence, lifestyle, and individual biology.
Semaglutide
Ozempic / Wegovy — GLP-1 only
~15%
avg. body weight loss
STEP 1 trial — 68 weeks at 2.4 mg/week
FDA Approved
Tirzepatide
Mounjaro / Zepbound — GLP-1 + GIP
~21%
avg. body weight loss
SURMOUNT-1 trial — 72 weeks at highest dose (15 mg/week)
FDA Approved
Retatrutide
Triple agonist — GLP-1 + GIP + Glucagon
~24%
avg. body weight loss
Phase 2 trial data — 48 weeks at highest dose (12 mg/week). Phase 3 trials ongoing; data continues to evolve.
Investigational — Phase 3